Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 15:378:213-219.
doi: 10.1016/j.jns.2017.05.025. Epub 2017 May 12.

In-vivo reflectance confocal microscopy of Meissner's corpuscles in diabetic distal symmetric polyneuropathy

Affiliations

In-vivo reflectance confocal microscopy of Meissner's corpuscles in diabetic distal symmetric polyneuropathy

Peter D Creigh et al. J Neurol Sci. .

Abstract

Objective: To evaluate in-vivo reflectance confocal microscopy (RCM) of Meissner's corpuscles (MC) in diabetic distal symmetric polyneuropathy (DSP).

Methods: Forty-three adults with diabetes and 21 control subjects underwent RCM of MC density at the fingertip of digit V, thenar eminence (TE), and arch of the foot, ankle skin biopsy for epidermal nerve fiber density (ENFD), electrophysiological studies, monofilament threshold testing, and timed vibration at the toe. Subjects with diabetes were subdivided into groups with and without clinical DSP using the American Academy of Neurology (AAN) case definition and neuropathy outcomes were compared across groups.

Results: Both diabetic groups (with and without AAN clinical DSP criteria) had objective evidence of peripheral sensory involvement using conventional sensory measures, although those with clinical DSP criteria had greater abnormalities. MC densities were lower in the entire diabetic group at the TE and digit V relative to controls. MC densities at all imaging sites were associated with corresponding conventional sensory measures. MC densities were reduced in subjects without AAN clinical DSP criteria at the TE and digit V compared to controls whereas conventional upper limb sensory measures did not differ between these groups.

Conclusions: In-vivo RCM of MC density at digit V is a non-invasive, painless, objective marker in diabetes that offers a window into early large fiber sensory nerve terminal loss. Further studies are needed to determine whether RCM of MCs can identify quantitative changes in DSP associated with disease progression or treatment.

Keywords: Diabetes; Epidermal nerve fiber density; Meissner's corpuscle; Peripheral neuropathy; Reflectance confocal microscopy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Meissner’s corpuscle densities for control subjects and subjects with diabetes
Meissner’s corpuscle (MC) densities for control subjects and all subjects with diabetes at the fingertip (D5), thenar eminence (TE), and foot arch. Box plots illustrate median and quartiles, with the diamond representing the mean. P values (two-tailed) are derived from analysis of covariance based on ranks; see text for details.
Figure 2
Figure 2. In-Vivo Reflectance Confocal Microscopy of Meissner’s corpuscles in control subjects and subjects with diabetes
Mosaic images obtained from the palmar surface of the distal phalanx of digit V using in-vivo reflectance confocal microscopy illustrating progressively lower Meissner’s corpuscle (MC) density between (A) a control subject, (B) a subject with diabetes without DSP, and (C) a subject with diabetes with DSP. White arrows highlight MCs. Black arrows highlight the absence of MCs.

References

    1. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817–824. - PubMed
    1. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes care. 2005;28:956–962. - PubMed
    1. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacology & therapeutics. 2008;120:1–34. - PMC - PubMed
    1. Zychowska M, Rojewska E, Przewlocka B, Mika J. Mechanisms and pharmacology of diabetic neuropathy - experimental and clinical studies. Pharmacological reports : PR. 2013;65:1601–1610. - PubMed
    1. Pasnoor M, Dimachkie MM, Kluding P, Barohn RJ. Diabetic neuropathy part 1: overview and symmetric phenotypes. Neurologic clinics. 2013;31:425–445. - PMC - PubMed

LinkOut - more resources